EnsiteVascular™ is led by status quo changers who seek innovation in medical devices like VCDs. SiteSeal® and SiteSeal® SV™ are breakthrough devices that solve the challenges of establishing hemostasis for endovascular physicians, patients and healthcare administrators alike. The time had come for a new approach to vascular closures, and EnsiteVascular’s VCDs are the result.For us, it’s not about putting another VCD on the market. It’s about leaving nothing behind. Because in our niche medical device market, the number of patients with coronary and peripheral arterial disease and structural heart disease is increasing. And, if we can make vascular closures outcomes better for everyone, then that’s what we needed to do.

Assumed responsibility for company with zero sales and over $1M debt and totally reorganized all functions of the company to include:-Elimination of non-revenue producing products and the development of viable ones that were then marketable-Obtained bank financing that included lines of credit at competitive rates enabling the company to grow unimpeded-Brought profitable products through the FDA to market ahead of schedule and under budget-Standardized Primus products into the two largest reference laboratories in the World enabling the company to become a worldwide recognized leader -Reorganized sales and marketing and distribution support in 15 countries to optimize revenue, gross margin, and EPS contribution from Instruments and Reagents resulting in one of the highest sales per employee ratios in the industryAction plan highlights:-Realigned sales and marketing staff to account for measurable revenue contribution by country-Designed and deployed selling strategy into hospital groups, physician office lab, and public health segments in the U.S.-Launched primary product under education branding campaign to expand product features and market awareness of differentiation which resulted in the company’s products being recognized far in excess of the market shareAccomplishments: -Organized and integrated sales, marketing and distribution network in 15 countries-Achieved 18 percent top line growth year on year while maintaining a 78 percent gross margin-Secured new product registrations in EU and China in order to sell into those markets-Maintained lowest personnel turnover rate possible vs. industry-Maintained highest sales per employee ratio vs. industry

Accomplishments: -Designed and implemented a broad-based market entry strategy for novel point of care, infectious disease, endocrinology and autoimmune products that enhanced company brand awareness before international, federal, and state agencies and penetrated new markets for this medical device manufacturing company, and its parent company’s family of diagnostic products. Plan highlights include:-Establishment of sales force for sole distribution of company’s autoimmune and infectious disease products-Formed alliances with key companies that led to successful sale of company-Established Phase III drug study division as adjunct to main division

Accomplishments: -Responsible for acquisition of all customers-Advised clients with respect to unique equity opportunities in the health-care industry -Successfully brought company to optimum position for eventual acquisition